Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SyntiGen
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SyntiGen is an engineered, non-pathogenic *Escherichia coli* (E. coli) live microbial therapy designed to function as an artificial antigen-presenting cell (APC) for cancer immunotherapy. Developed by researchers at the Dana-Farber Cancer Institute and the Koch Institute at MIT, SyntiGen is surface-modified to display a peptide-major histocompatibility complex class I (pMHC-I) fusion protein alongside co-stimulatory ligands such as CD80 or OX40L. This platform directly primes and activates tumor-specific cytotoxic CD8+ T cells within the immunosuppressive tumor microenvironment, bypassing the tumor's ability to suppress natural APCs. SyntiGen can be administered intravenously or utilized ex vivo to prime tumor-infiltrating lymphocytes (TILs) for adoptive cell transfer.
- Other names
- SyntiGens
02
Targets
γδ TCR (T-cell receptor)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on SyntiGen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SyntiGen.